share_log

MusclePharm (OTCMKTS:MSLP) Shares Cross Below 200-Day Moving Average of $0.23

Defense World ·  Sep 9, 2022 03:21

Shares of MusclePharm Co. (OTCMKTS:MSLP – Get Rating) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.23 and traded as low as $0.20. MusclePharm shares last traded at $0.20, with a volume of 110 shares traded.

MusclePharm Price Performance

The firm has a 50 day simple moving average of $0.18 and a 200-day simple moving average of $0.23. The company has a market cap of $6.67 million, a price-to-earnings ratio of -0.34 and a beta of 0.40.

MusclePharm Company Profile

(Get Rating)

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products.

Featured Articles

  • Get a free copy of the StockNews.com research report on MusclePharm (MSLP)
  • Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
  • Are These Green Energy Companies Right For Your Portfolio?
  • When Will the Hangover Finally Be Over for Seagate Technology?
  • Does Enphase Energy Have the Juice to Keep Powering Higher?
  • The One Hydrogen Fuel Cell Stock To Rule Them All

Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment